Income Statement (TTM)
Kintor Pharmaceutical Limited Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 34 | 34 | 34 | 17 | 2 | 5 | 8 | 11 |
| Change (%) | 100.00 | 0.00 | 0.00 | -50.00 | -85.39 | 100.00 | 59.84 | 37.44 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | -1 | 3 | 7 | 10 | |||||
| Change (%) | -392.64 | 117.08 | 53.93 | ||||||
| % of Revenue | -42.66 | 62.42 | 84.77 | 94.95 | |||||
| Gross Operating Profit | 17 | 34 | 34 | 34 | 17 | 4 | 2 | 1 | 1 |
| Change (%) | 100.00 | 0.00 | 0.00 | -50.00 | -79.16 | -47.32 | -35.23 | -54.40 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 142.66 | 37.58 | 15.23 | 5.05 |
| SG&A | 116 | 118 | 128 | 138 | 145 | 81 | 90 | 89 | 87 |
| Change (%) | 1.89 | 8.64 | 7.95 | 5.15 | -44.50 | 10.98 | -1.21 | -1.23 | |
| % of Revenue | 676.39 | 344.58 | 374.34 | 404.10 | 849.82 | 3,229.08 | 1,791.78 | 1,107.39 | 795.85 |
| R&D | 615 | 768 | 857 | 947 | 887 | 446 | 78 | 83 | 87 |
| Change (%) | 24.82 | 11.65 | 10.43 | -6.28 | -49.75 | -82.47 | 5.94 | 5.61 | |
| % of Revenue | 3,594.71 | 2,243.39 | 2,504.72 | 2,766.04 | 5,184.82 | 17,835.20 | 1,562.86 | 1,035.84 | 795.94 |
| OpEx | 714 | 869 | 969 | 1,070 | 1,020 | 515 | 151 | 161 | 170 |
| Change (%) | 21.76 | 11.56 | 10.37 | -4.71 | -49.53 | -70.67 | 6.39 | 6.01 | |
| % of Revenue | 4,169.57 | 2,538.42 | 2,831.99 | 3,125.55 | 5,956.68 | 20,580.94 | 3,018.00 | 2,008.82 | 1,549.44 |
| Operating Income | -697 | -835 | -935 | -1,036 | -1,002 | -512 | -146 | -153 | -159 |
| Change (%) | 19.84 | 12.04 | 10.75 | -3.21 | -48.92 | -71.51 | 4.56 | 4.36 | |
| % of Revenue | -4,069.57 | -2,438.42 | -2,731.99 | -3,025.55 | -5,856.68 | -20,480.94 | -2,918.00 | -1,908.82 | -1,449.44 |
| Interest Expense | -3 | -2 | -3 | -3 | -6 | -9 | -9 | -8 | -6 |
| Change (%) | -19.87 | 17.72 | 15.05 | 71.18 | 56.78 | 2.33 | -16.06 | -19.13 | |
| % of Revenue | -18.19 | -7.29 | -8.58 | -9.87 | -33.79 | -362.64 | -185.54 | -97.44 | -57.34 |
| Net Income | -740 | -842 | -938 | -1,035 | -995 | -538 | -155 | -161 | -167 |
| Change (%) | 13.74 | 11.44 | 10.26 | -3.88 | -45.93 | -71.12 | 3.79 | 3.65 | |
| % of Revenue | -4,325.82 | -2,460.04 | -2,741.36 | -3,022.69 | -5,810.72 | -21,509.88 | -3,105.84 | -2,016.76 | -1,521.00 |
Source: Capital IQ
